drugset / Trial / NCT04836052

Omega-3 Oil Use in COVID-19 Patients in Qatar

NCT04836052

Phase 3 Unknown 372 enrolled Hamad Medical Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

COVID-19 infection has been widely spread since December 2019 and causing many comorbidities and fatalities. The most common clinical presentation of COVID-19 patients admitted to ICUs is respiratory failure , hypoxia and acute lung injury. While new therapies and vaccines are urgently being investigated, they may take an inordinate time to get to right people. Omega-3-oil has been shown to have less proinflammatory mediators that may have immunomodulating, anti-inflammatory and antiviral effect. Two main fatty acids in omega-3-oil including eicosapentaenoic acid and docosahexaenoic acid have shown benefit in patients with ARDS as well. So, the investigators proposed a randomized controlled study to evaluate the effectiveness of omega-3-oil supplementation 2 gm PO/NGT/OGT twice daily for 28 days or till discharge or till death in COVID-19 critically ill patients admitted to ICU who require oxygen support.

Timeline

Start
2020-12-24
Primary completion
2021-08-24
Completion
2021-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Lovaza Other / unclassified 2 g Oral

Indications